Ensign Peak Advisors
TYRA icon

Ensign Peak Advisors’s Tyra Biosciences TYRA Stock Holding History

Ensign Peak Advisors’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.68M Buy
146,537
+72,473
+98% +$2.4M 0.01% 577
2026
Q1 		$2.84M Buy
+74,064
New +$2.4M 0.01% 646
2024
Q4 		– Sell
-115,616
Closed -$2.72M – 1727
2024
Q3 		$2.72M Sell
115,616
-74,941
-39% -$1.57M ﹤0.01% 823
2024
Q2 		$3.05M Buy
+190,557
New +$3.28M 0.01% 767
2022
Q2 		– Sell
-125,000
Closed -$1.34M – 2203
2022
Q1 		$1.34M Hold
125,000
– – ﹤0.01% 1049
2021
Q4 		$1.76M Hold
125,000
– – ﹤0.01% 1013
2021
Q3 		$2.2M Buy
+125,000
New +$2.39M ﹤0.01% 1066

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Ensign Peak Advisors's TYRA Position: Q2 2026 in Review

Ensign Peak Advisors increased its Tyra Biosciences (TYRA) stake by 98% in Q2 2026, buying an estimated $2.4M and bringing the position to 146,537 shares worth $4.68M. The position accounts for 0.01% of the portfolio, ranked #577.

Ensign Peak Advisors first reported a position in TYRA in Q3 2021 and has held it in 7 quarters since. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Ensign Peak Advisors held 146,537 shares of Tyra Biosciences worth $4.68M as of Q2 2026.
  • Ensign Peak Advisors bought 72,473 Tyra Biosciences shares in Q2 2026, an estimated $2.4M.
  • Tyra Biosciences made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #577 holding.
  • Ensign Peak Advisors first reported a position in Tyra Biosciences in Q3 2021 and has held it in 7 quarters since.
  • 169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.